Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees is well positioned for growth with the potential success of its current pipeline in infectious diseases. The company's ARAKODA commercial buildout and partnerships with GoodRx and Runway Health demonstrate efforts to improve affordability and broaden patient access. However, risks associated with regulatory approval and potential dilution from future capital raises may impact the company's stock performance. The recent 1:4 reverse stock split and additional dilution from recent ATM sales have led to an adjusted price target of $4.20, representing 130% upside from the current share price. Fundamentals of the company, such as cash on hand and potential future financing, should also be monitored closely as they may affect the company's financial health.

Bears say

60 Degrees is facing challenges with their ARAKODA revenue trajectory, potential limitations in funding future clinical development programs, and a low cash balance of $3.3 million. Additionally, their Q1 FY26 product revenue has declined due to higher returns and lower sell-through, with US pharmacy/dispensary unit sales decreasing by 19%. While the company shows potential in filling an unmet need in infectious diseases, the current financial constraints and lack of visibility on ongoing development plans make it difficult to maintain a positive outlook. Their clinical progress on tafenoquine for Babesiosis shows promise, but funding limitations and uncertainties surrounding their financials warrant a rating downgrade to Neutral at this time.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Jun 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.